{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-011181","form_type":"8-K","ticker":"IRD","cik":"0001228627","company_name":"Opus Genetics, Inc.","filed_at":"2025-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.133736+00:00","generated_at":"2026-05-24T01:32:58.386123+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Opus Genetics reports FY2024 net loss of $57.5M; gene therapy pipeline advances","bullets":["Net loss of $57.5M ($2.15/sh) vs $10.0M in 2023; revenue $11M from Viatris license.","Cash $30.3M at year-end; March 2025 financing raised $21.5M, extending runway into H2 2026.","OPGx-LCA5 Phase 1/2 shows durable response at 12 months; Type D FDA meeting held; pediatric enrollment started.","OPGx-BEST1 IND-enabling studies done; Phase 1/2 initiation planned for 2025 with preliminary data by Q1 2026.","Phentolamine LYNX-2 (dim light) and VEGA-3 (presbyopia) Phase 3 trials fully enrolled; topline data expected mid-2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-011181","json":"https://secwatch.observer/filing/0001140361-25-011181.json","markdown":"https://secwatch.observer/filing/0001140361-25-011181.md","text":"https://secwatch.observer/filing/0001140361-25-011181.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1228627/000114036125011181/0001140361-25-011181-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1228627/000114036125011181/ef20046473_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T01:32:58.386123+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}